Biomea Fusion Ownership
| BMEA Stock | USD 1.85 0.03 1.60% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 36 M | Current Value 37 M | Avarage Shares Outstanding 26.9 M | Quarterly Volatility 9.9 M |
Biomea Stock Ownership Analysis
About 45.0% of the company shares are held by institutions such as insurance companies. The book value of Biomea Fusion was currently reported as 0.77. The company recorded a loss per share of 3.54. Biomea Fusion had not issued any dividends in recent years. Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The company was incorporated in 2017 and is headquartered in Redwood City, California. Biomea Fusion operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more info on Biomea Fusion please contact the company at 650 980 9099 or go to https://biomeafusion.com.Biomea Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomea Fusion is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomea Fusion backward and forwards among themselves. Biomea Fusion's institutional investor refers to the entity that pools money to purchase Biomea Fusion's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2025-03-31 | 472.4 K | Northern Trust Corp | 2025-03-31 | 297.6 K | Millennium Management Llc | 2025-03-31 | 281.7 K | Renaissance Technologies Corp | 2025-03-31 | 278.1 K | Nuveen, Llc | 2025-03-31 | 270.1 K | Aqr Capital Management Llc | 2025-03-31 | 264 K | Woodline Partners Lp | 2025-03-31 | 240.8 K | Ubs Group Ag | 2025-03-31 | 236.9 K | Charles Schwab Investment Management Inc | 2025-03-31 | 181.4 K | Fmr Inc | 2025-03-31 | 5.4 M | Cormorant Asset Management, Llc | 2025-03-31 | 3.6 M |
Biomea Fusion Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomea Fusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomea Fusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomea Fusion insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biomea Fusion Outstanding Bonds
Biomea Fusion issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomea Fusion uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomea bonds can be classified according to their maturity, which is the date when Biomea Fusion has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomea Fusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomea Fusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomea Fusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomea Fusion Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomea Fusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.